Flare phenomenon bone scan. html>xt

In order to effectively manage these patients, it is essential to have consistent, reproducible and validated methods of assessing response to therapy. A higher percentage of patients with bone metastases showed a flare (41%) than has previously been reported. [1,2,3] Flare response has also been described with 18 F bone PET scanning. DOTA-ibandronic acid (DOTA-IBA) is a new prodrug that targets bone metastases and can be labeled with 177Lu. Recently, highly successful results have been obtained targeting the prostate specific membrane antigen (PSMA), both for diagnostic and therapeutic purposes. Sep 19, 2018 · Furthermore, its efficacy is impaired by the bone scan flare phenomenon (the development of new lesions on a first follow-up scan that may actually do not represent disease progression). The flare phenomenon with various chemotherapeutic and hormonal agents is well acknowledged in bone scintigraphy. An increased uptake of the radioactive substance can be detected up to 6 months after treatment of bone metastases [6, 22]. Feb 24, 2021 · This review aims at highlighting new evidence on flare phenomenon arising after the introduction of new drugs extending across the biochemical, radiographic and clinical spectrum of the disease. Repeated quantitative bone scintigraphy in patients with prostatic carcinoma treated with orchiectomy. ‘I,,uIj. Am J Roentgenol 1984;142: 773 Apr 1, 2017 · However, in previous study, it was reported that a bone scan flare phenomenon with AA treatment was observed in 12 of 33 patients (33%). 3, 4, 5 This phenomenon represents rapid bone repair around the responding lesion (increased osteoblastic activity) and may be predictive of 1. It has been well documented in patients with metastatic breast or prostate carcinoma, and recently reported in those with lung ca … Oct 1, 2018 · The bone scintigraphy after the end of the treatment showed an apparent aggravation of the lesions, corresponding to a flare phenomenon, with an almost complete resolution after three months, and the patient maintained a scintigraphic response for seven months. Bone scintigraphy flare phenomenon was defined as ≥ 2 new lesions after 3 cycles of radium-223 with no additional new lesions on the scan at the end of radium-223 treatment irrespective of PSA level. edu no longer supports Internet Explorer. Jun 12, 2023 · a high signal may be seen in surrounding bone marrow and soft tissues due to the edema "flare phenomenon" 10. 8. Dec 1, 2016 · Download Citation | On Dec 1, 2016, Sangki Lee and others published The Flare Phenomenon in a Patient with Advanced Gastric Cancer with Bone Metastases | Find, read and cite all the research you Jun 1, 2011 · The flare phenomenon on a bone scan within three months of therapy is typically due to a reparative process and characterized by increased lesion intensity or number in the setting of improved PSA. . A flare phenomenon is usually seen during the first 3 months after chemotherapy and represents a favourable response to therapy. Aug 1, 2011 · The flare phenomenon on a bone scan within three months of therapy is typically due to a reparative process and characterized by increased lesion intensity or number in the setting of improved PSA. Repeat bone scans were at 6 weeks (flare usually assessed at 3 months) following instigation of treatment. After the first clinically indicated bone scan, the patients received zoledronic acid within 72 hours and underwent a second bone scan within another 72 hours. May 5, 2022 · Furthermore, after 6 mo of continued treatment, bone scan revealed reduced or stable lesions, and this was termed the “bone flare” phenomenon. Indeed, the healing processes of new bone formation can cause a paradoxical initial increase in tracer uptake, and studies performed during this phase are likely to show increased intensity and number Jun 1, 2012 · A flare reaction on bone scan is an unusual phenomenon in prostatic cancer; in general, serial scans accurately depict the activity of bony metastases in these patients. Early bone scan flare before 2 months has previously been described in prostate cancer and although it is uncertain whether this Oct 1, 2018 · Figure 1 Posterior View of Bone Scintigraphy and Bone Scan Index in Patient With Increase in Bone Lesions. We also review the biology of bone Flare phenomenon is a well-known process noted in bone scintigraphy during the course of treatment of osseous metastases. Bone scintigraphy data acquired during treatment with radium-223 should be interpreted with caution, and treatment should not be changed according to increase in number of lesions on bone scintigraphy alone after 3 … The bone scan flare phenomenon is defined as worsening of bone lesions with subsequent improvement during effective cancer treatment. Aug 1, 2002 · The bone scan flare phenomenon is known to occur in many cancers [14] [15] [16], and involves an increase in bone scan uptake during the healing process, usually 3-6 months after the commencement Feb 1, 2016 · Bone metastases are common in patients with advanced breast cancer. Keywords: bone metastasis; castration-resistant prostate cancer; flare phenomenon; imaging; systemic treatment. ” Although the early appearance of flare at PET is a positive prognostic marker, prolonged persistence of this phenomenon could eventually disturb the correct image interpretation. 3. The value of bone metabolic markers in monitoring the therapeutic response A flare reaction on bone scan is an unusual phenomenon in prostatic cancer; in general, serial scans accurately depict the activity of bony metastases in these patients. Twenty-three breast cancer patients with bone metastases treated by combined … Mar 22, 2019 · A healing “flare phenomenon” has been described as increased radiotracer uptake in an area of previously noted skeletal metastasis on a bone scan associated with increased sclerosis on radiographs or CT scan. A flare response on Tc-99m bone scan indicates progression of bone metastasis despite the effectiveness of treatment. The ALP flare phenomenon is also often Jul 1, 1994 · PURPOSE: To identify the frequency, characteristics, and prognostic significance of scintigraphically detected healing flare in patients with breast cancer metastatic to bone. Mar 13, 2024 · OBJECTIVE: This study aimed to determine the prognostic value of the flare phenomenon in patients with metastatic castration-resistant prostate cancer (mCRPC) using the bone scan index (BSI) derived from 99m Tc-methylenediphosphonate (MDP) bone scintigraphy images. As a consequence, new lesions on M3 bone scan have to be confirmed within a delay of 6 weeks or more by a second scan, which has to show at least 2 new lesions to conclude to a progression. Tumor progression versus bone scan The radionuclide bone scan 3 months after the initiation of treatment for advanced cancer of the prostate occasionally shows apparent progression of individual lesions despite clinical improvement. We report a case of osseous flare response in the thoracic spine, correlating its appearance on 18 F-FDG and 18 F-fluoride ion PET, CT, technetium-99m medronate (99m Tc-MDP) bone scanning, and gadolinium-enhanced MRI. Outcomes of 101 patients (aged 21-71 years) with skeletal metastases Purpose: The bone scan flare phenomenon has been evaluated in various cancers in the presence of positive response to therapy. edu Academia. 15 The first patient with low back pain and a positive bone scan was put onto daily leuprolide injections on December 13, 1986 and developed shortness of breath on January 5, 1987, succumbing 3 days later. Bone scan flare seriously complicates evaluations of the therapeutic response of bone metastases. Sep 9, 2011 · While it is recognized that bone flare is a rare phenomenon, an increase in baseline skeletal activity and appearance of new bone lesions despite apparent response or stable disease elsewhere should be interpreted with caution to avoid erroneously suggesting progressive disease. In the baseline scan, multiple bone lesions are observed (yellow circles), which subsequently become indistinguishable in the first post-treatment scan due to diffusely increased uptake activity throughout the bones. AJR:142, April1984 FLAREPHENOMENON ONBONE SCAN 775-. Jul 16, 2014 · Flare phenomenon can affect 99m Tc-MDP bone scan’s assessment of tumor response to therapy. The osteoblastic bone flare or response is the paradoxical phenomenon of increase in the quantity and/or density of bone lesions in the presence of well-documented disease response to treatment in other tumor sites. 2. Apr 14, 2020 · For patients with suspected bone tumor of the spine, non-contrast CT would initially be recommended to identify any sclerotic rim, intratumoral calcifications and location of the lesion, followed by an MRI to look for the flare phenomenon, and then an 18 F-FDG PET to determine the metabolic level of the flare tissues. On bone scintigraphy a flare phenomenon on therapy with radium-223 may be observed; this should be taken into Metabolic flare is a well-documented phenomenon reported in metastatic breast and prostate cancer. When active arterial hemorrhage is present in a liquefied hematoma that has a hematocrit effect, a signal flare phenomenon may be seen as a linear, high attenuating focus in the dependent layer as well as very high-attenuation foci at the boundary A patient undergoing cytostatic therapy for osteosarcoma of the right humerus had bone scans at 2-mo intervals and a skeletal focus of increased radiotracer accumulation occurred and subsequently was confirmed by CT and MRI, confirming the presence of the flare phenomenon in skeletal metastases in primary malignant bone tumors. T1 C+ (Gd): this is a highly vascular tumor and therefore typically avidly enhances, with associated enhancement of the surrounding soft tissues 9. Despite a favorable response to therapy, there is a paradoxical increase in radiopharmaceutical uptake. Metabolic flare is a well-documented phenomenon reported in metastatic breast and prostate cancer. The bone scan flare phenomenon, defined as an increase in the number or intensity of bone lesions with subsequent improvement while the patient is receiving chemotherapy, has been described in solid tumors including breast cancers and small-cell lung cancers. May 7, 2015 · The flare phenomena and bone scan response we observed have not previously been described with radium-223. A flare reaction on bone scan is an unusual phenomenon in prostatic cancer; in general, serial scans accurately depict the activity of bony metastases in these patients. The aim of this study was to determine whether flare phenomenon occurs in non-small-cell lung May 15, 2012 · To evaluate the effect of the treatment, we arranged another bone scan to monitor the bone lesions after radiotherapy. Given the significant associated morbidity, the introduction of new, effective systemic therapies, and the improvement in survival time, early detection and response assessment of skeletal metastases have become even more important. In those with bone lesions of uncertain aetiology a flare occurred in 20%. This case suggests that the degree and duration of bone scan response may be predictive of overall survival benefit. MATERIALS AND METHODS: Findings on bone scans and concomitant radiographs of 1,188 patients were reviewed. To determine the incidence and clinical significance of this so-called flare phenomenon, serial bone scans were reviewed in 33 patients with carcinoma of the prostate and bony metastases, who were Apr 1, 2010 · Background. Also 18F-NaF PET imaging is considered an accurate modality for detecting bone metastases. 8% and a particularly high prevalence in Americas, Oceania, most parts in Africa, western Europe, and Japan [ 1 ]. Osteoblastic flare phenomenon has been described in detail using 99m Tc-MDP scintigraphy . The findings show that the flare is common during the first 3 months of gefitinib initiation; hence, a repeat bone scan should be reserved for later in the treatment course. Nov 1, 2005 · The bone scan flare phenomenon, defined as an increase in the number or intensity of bone lesions with subsequent improvement while the patient is receiving chemotherapy, has been described in Oct 27, 2023 · Bone scan images illustrating the super scan phenomenon. We systematically evaluated imaging data of 19 patients treated with radium-223. The bone scan response to radium-223 has only been described in one single center trial of 14 patients, none of whom achieved the outstanding bone scan response presented in the current case. Progression of bone and lymph node metastases was evident on CT scan of the abdomen and a bone scan. Bone scintigraphy flare in patients undergoing therapy with radium-223 was observed. We aimed to review current literature on comparative performances of 18F-FDG and 18F-NaF PET imaging for assessing bone metastases from BC. Google Scholar. Sep 29, 2009 · The flare phenomenon on radionuclide bone scan in patients with prostate cancer has been reported at anywhere between 6 and 25% and is also a feature observed on plain film. The second patient with back pain and a positive bone scan To determine the incidence and clinical significance of this so-called flare phenomenon, serial bone scans were reviewed in 33 patients with carcinoma of the prostate and bony metastases, who were receiving endocrine treatment for the first time. The flare phenomenon is a transient increase in the number or intensity of lesions on bone scans after treatment, signifying curative effect. 23 This highlights that we must avoid premature discontinuation of AA treatment, not only because of a PSA flare, but also because of transient bone scan progression. The value of bone metabolic markers in monitoring the therapeutic response for bone metastases in breast cancer was assessed. The flare response refers to an Mar 1, 2009 · However, a paradoxical flare phenomenon with increase in bone lesion activity despite overall response has been described in several other solid tumors (breast, prostate, small cell lung cancer). Favorable prognosis, with fewer disturbances from other factors such as the use of abiraterone or/and enzalutamide, PSA changes, and BSI, was attainable in cases when the mCRPC patient demonstrated flare phenomenon. ISI. Eur J Nucl Med 1988;14:203–206. During the initial period of treatment with medroxyprogesterone acetate in patients with hormone-resistant prostatic cancer, a marked clinical flare reaction, mainly with bone pain exacerbation was observed . 4. It may be because of Jun 7, 2020 · The signal flare phenomenon is a useful sign to identify active bleeding in a liquefied hematoma with hematocrit effect on dynamic CT scan images. To determine the incidence and clinical significance of this so-called flare phenomenon, serial bone scans were reviewed in 33 patients with carcinoma of the prostate and bony metastases, who were Jan 21, 2020 · Indeed, new isolated lesions at M3 can be a sign of a flare-up phenomenon, which is an early paradoxical worsening bone scan . Follow-up bone scintigraphy at least every 3 months could help to determine the prog … Oct 10, 2009 · The flare phenomenon on radionuclide bone scan in patients with prostate cancer has been reported at anywhere between 6 and 25% and is also a feature observed on plain film. To determine the incidence and clinical significance of this so-called flare phenomenon, serial bone scans were reviewed in 33 patients with carcinoma of the prostate and bony metastases, who were Purpose: The bone scan flare phenomenon, defined as an increase in the number or intensity of bone lesions with subsequent improvement while the patient is receiving chemotherapy, has been described in solid tumors including breast cancers and small-cell lung cancers. 11 In one study, bone marrow imaging with technetium 99m anti-NCA-95 monoclonal antibody detected almost twice the number of lesions observed on conventional methylene diphosphonate scans; however Mar 9, 2016 · This increase, specifically observed in bone scan, is commonly referred to as flare phenomenon. 18F-fluoride positron emission tomography/computed tomography has shown improved sensitivity and specificity over bone scintigraphy, but because of Flare reactions from tamoxifen are also known in the treatment of metastatic breast and advanced endometrial cancers . Mar 13, 2024 · Objective This study aimed to determine the prognostic value of the flare phenomenon in patients with metastatic castration-resistant prostate cancer (mCRPC) using the bone scan index (BSI) derived from 99mTc-methylenediphosphonate (MDP) bone scintigraphy images. Crossref. Comprehensive investigations in patients with metastatic prostate cancer have shown the flare to peak at weeks 6–8 of treatment follow-up [ 18 , 19 ]. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer (PDF) The flare phenomenon on radionuclide bone scan in metastatic prostate cancer | Jeffrey Pollen - Academia. Kim G, Pazdur R. Due to dramatic and prompt response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in a subgroup of lung cancer patients, flare phenomenon may be observed. Jul 18, 2022 · Flare Phenomenon- Flare phenomenon or osteoblastic flare phenomenon is the interval visualization of bone lesions with sclerotic rim previously not visible on a radiograph in the follow-up of cancer patients. I. EXINI 4 Bone ® software (EXINI Diagnostics, Lund, Sweden Oct 1, 2018 · For this analysis, all bone scintigraphy scans were analyzed visually by an experienced nuclear medicine physician (JM). Jan 5, 2022 · The flare phenomenon (FP) on bone scintigraphy after the initiation of systemic treatment seriously complicates evaluations of therapeutic response in patients with bone metastases. PurposeBone scintigraphy (BS) lacks sensitivity for detecting very early skeletal metastases (SM) in prostate cancer (PC) and is often limited by poor specificity. Nov 9, 2018 · The presence of a flare phenomenon must be accounted for when determining imaging schedules for patients receiving therapy for mCRPC. To determine the incidence and clinical significance of this so-called flare phenomenon, serial bone scans were reviewed in 33 patients with carcinoma of the prostate and bony metastases, who were The flare phenomenon following initial hormone therapy can be used to improve both sensitivity and specificity of bone scintigraphy in PC. Bone metastases were identified in 11% of Bone is the most common site for breast cancer metastases, occurring in up to 70% of those with metastatic disease. Although generally accepted as a healing or reactive process, the underlying mechanisms of flare remain unclear. As there was a remarkable discrepancy between the partial response seen in the primary tumor and non-osseous metastatic locations, the possibility of a bone flare phenomenon was considered. The aim of this study was to determine whether flare phenomenon occurs in non-small-cell lung cancer patients, especially adenocarcinoma in East-Asians, who respond dramatically and promptly to gefitinib. Methods A literature search for PET studies The bone scan index (BSI) is an established quantitative tool for assessing metastatic bone lesions in mCRPC and hormone-sensitive prostate cancer. PubMed. Google Scholar Sundkvist GMG, Ahlgren L, Lilja B, Mattsson S, Abrahamsson PA, Wadström LB. Serial bone scans were reviewed in 33 patients with carcinoma of the prostate and bony metastases, who were receiving endocrine treatment for the first time, to determine the The flare phenomenon is a transient increase in the number or intensity of lesions on bone scans after treatment, signifying curative effect of DOTA-ibandronic acid (DOTA-IBA) in a 58-year-old woman with bone metastasis. 32 μg/L). The flare phenomenon is defined as bone-scan and serum alkaline phosphate (ALP) findings that show disease progression after treatment despite indications of a good therapeutic response in terms of clinical symptoms or decreased tumor size on computed tomography (CT) scans. 4, The flare phenomenon on radionuclide bone scan in metastatic prostate cancer May 7, 2015 · Background Radium-223 has been shown to improve overall survival in men with metastatic castration-resistant prostate cancer with symptomatic bone metastases. The bone-scan flare phenomenon was first described in 1972 by Greenberg Jun 1, 2011 · The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Jun 1, 2011 · The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. When the flare tissues Bone scan flare seriously complicates evaluations of the therapeutic response of bone metastases. About 10‒15 months after … Bone flare phenomenon refers to a specific appearance of a lesion in the bone on the scan previously undetected on prior scans. The aim of this study was to determine whether flare phenomenon occurs in non Mar 13, 2024 · The bone flare phenomenon (flare) is defined as an initial improvement after therapy followed by apparent progression identified by bone scintigraphy . Distinguishing flare phenomenon from disease progression is challenging and often requires additional evaluation with other Measuring a bone resorption marker, ICTP, allows clinicians to monitor patients' responses to CAF therapy and may prevent prolonged ineffective therapy or unnecessary changes in therapy as a result of the flare phenomenon. The regions of interest on the bone scan were read in triplicate, and the mean count per pixel was calculated for the mandible (C(M)), left femur (C(FL)), right femur (C(FR)), and thigh Therefore, this flare phenomenon might be able to identify more aggressive Bone flare is a phenomenon that has already been observed in bone scintigraphy as either an increase in metabolic The radionuclide bone scan 3 months after the initiation of treatment for advanced cancer of the prostate occasionally shows apparent progression of individual lesions despite clinical improvement. If there is a subsequent decrease uptake in these lesions on repeat exam in 2-3 months, it then likely represents a flare phenomenon. View Show abstract Jul 8, 2021 · The similarity in uptake mechanism of 18 F-NaF to conventional bone scintigraphy agents such as 99m Tc-methylene diphosphonate means that it is subject to the flare phenomenon where there can be an initial increase in activity during an osteoblastic healing phase in metastases after successful therapy. Nuclear medicine This occurrence in a bone scan is well-known as “flare phenomenon. The purpose of this study was to verify the existence of the bone May 1, 2016 · Discussion. During treatment, the laboratory results of patients with the bone flare phenomenon showed no significant change in the alkaline phosphatase level, however, PSA level continued to decrease. Similarly, CT can show an increase in The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Sep 9, 2010 · 1. This process occurs when bone metastases respond to chemotherapy and osteoblastic activity sets in. The aim of this study was to evaluate whether serum alkaline phosphatase (ALP) can differentiate FP from disease progression on bone scintigraphy in these patients. Laboratory results were significant for a raise in ALP concentration (980 U/L) with a mild but significant increase in PSA concentration (1. Increased uptake may be The radionuclide bone scan 3 months after the initiation of treatment for advanced cancer of the prostate occasionally shows apparent progression of individual lesions despite clinical improvement. It has been well documented in patients with metastatic breast or prostate carcinoma, and recently reported in those with lung cancer. Purpose The bone scan flare phenomenon, defined as an increase in the number or intensity of bone lesions with subsequent improvement while the . Bone metastases occurred in 426 patients. This typically indicates healing of previously inconspicuous lesions and does not indicate disease progression. Case presentation In this case report, we Feb 24, 2021 · He did not report any pain, and physical examination was unchanged. “Flare” phenomenon has been primarily reported as a transient increase in the number or intensity of lesions on bone scans in patients receiving hormonal or chemotherapy. Prostate cancer is the second most prevalent type of malignancy among men, with a mortality rate of 6. Feb 25, 2024 · After the start of successful treatment, the interpretation of response on bone scintigraphy may be temporarily hampered by the flare phenomenon. We subsequently reported two patients who experienced sudden death during flare. Jul 1, 2002 · The bone flare phenomenon occurs in NSCLC and renders bone scintigraphy less useful in the evaluation of tumoral response in the patients in whom it is considered likely, and thus reduces the utility of bone scints in the follow-up of these patients. Although current literature suggests repeat bone scans coupled with PSA levels at 3 and 6 months following chemotherapy to detect flare phenomenon and repeat CT scans every 2–4 months following Docetaxel therapy, there is no current consensus on the timing Nov 1, 2012 · The bone flare phenomenon on radionuclide bone scan, characterised by an increased tracer uptake at the sites of bone metastases and/or the appearance of new lesions shortly after the commencement of treatment has previously been described in breast and prostate cancer, while it has been reported in case reports in non small cell lung cancer (NSCLC) and in a small series in SCLC. Dec 17, 2014 · The bone scan flare phenomenon has been evaluated in various cancers in the presence of positive response to therapy. We present current clinical practice of imaging response assessment of bone metastases. Interestingly, a flare phenomenon became apparent within short time after radiotherapy. Am J Radiol 1984;142:773–776. The radionuclide bone scan 3 months after the initiation of treatment for advanced cancer of the prostate occasionally shows apparent progression of individual lesions despite clinical improvement. A flare reaction was seen in two (6%) of 33 bone scans obtained 3 months after initiation of treatment. Am J Roentgenol 1984;142:773–6. Flare phenomenon has also been proposed as an Aug 10, 2010 · In our study we performed the second scan at 6 weeks and it is possible that some scintigraphic flares begin to resolve by 3 months and that the earlier 6-week time point is more sensitive for the detection of flare. A patient undergoing cytostatic therapy for osteosarcoma of the Jan 5, 2022 · Abstract. Jan 1, 2023 · The flare phenomenon with various chemotherapeutic and hormonal agents is well acknowledged in bone scintigraphy. Breast or prostate cancer patients with bone Nov 20, 2000 · Bone marrow scanning has been reported to be more sensitive than conventional bone scanning in the detection of metastases from prostate carcinoma. Shown (Left to Right) are Bone Scintigraphy and Bone Scan Index at Baseline, After 3 Cycles of Radium-223 Showing Increase in number of Bone - "Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium‐223?" This patient was started on first line tyrosine kinase inhibitor (TKI) and seemingly developed new bone metastases under this treatment. It may be because of an increase in blood flow caused by an inflammatory response or an increased turnover of hydroxyapatite in the new bone laid down as part of the Apr 23, 2018 · Micro-AbstractRadium-223 is an approved survival-prolonging treatment option in men with castration-resistant prostate cancer and bone metastases, but data on treatment monitoring by imaging are scarce. However, very few cases have been documented on PET/CT. "Flare" phenomenon has been primarily reported as a transient increase in the number or intensity of lesions on bone scans in patients receiving hormonal or chemotherapy. The flare phenomenon (FP) on bone scintigraphy after the initiation of systemic treatment seriously complicates evaluations of therapeutic response in patients with bone metastases. It is regarded as an imag-ing biomarker due to its signicant contribution to monitor - ing bone lesions and prognostic evaluations [–7]. There is no current determination for when bone scintigraphy would become negative after Docetaxel therapy for lytic lesions. Also scintigraphic flare of SM can occur following effective treatment and mislead an early Jan 11, 2016 · Background For decades, planar bone scintigraphy has been the standard practice for detection of bone metastases in prostate cancer and has been endorsed by recent oncology/urology guidelines. Methods We categorized 72 patients from the PROSTAT-BSI registry with mCRPC who were followed-up for 2 years after starting Feb 22, 2016 · Although current literature suggests repeat bone scans coupled with PSA levels at 3 and 6 months following chemotherapy to detect flare phenomenon and repeat CT scans every 2–4 months following Docetaxel therapy, there is no current consensus on the timing of bone scintigraphy for evaluation of treatment response, yet experts recommend that Jun 30, 2017 · As it can be misinterpreted as progression in bone metastasis, follow up bone scintigraphy for 6 months or more is the rule. Although planar bone scanning has recognized limitations, in particular, poor specificity in Mar 31, 2020 · Purpose In patient with breast cancer (BC), 18F-FDG PET/CT is widely used for assessing skeletal metastatic involvement. It is a sensitive method with modest specificity. Purpose: The bone scan flare phenomenon has been evaluated in various cancers in the presence of positive response to therapy. xq wr bj hm xt xz ab xq ue rd